Alpha 1-antitrypsin deficiency secondary prevention

Alpha 1-antitrypsin deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alpha 1-antitrypsin deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alpha 1-antitrypsin deficiency secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alpha 1-antitrypsin deficiency secondary prevention
CDC on Alpha 1-antitrypsin deficiency secondary prevention
Alpha 1-antitrypsin deficiency secondary prevention in the news
Blogs on Alpha 1-antitrypsin deficiency secondary prevention
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes effective secondary prevention strategy for alpha1-antitrypsin deficiency (AATD) patient is to avoid cigarette smoking. Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls. Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.

Secondary Prevention

Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes :

The most effective secondary prevention strategy for alpha1-antitrypsin deficiency (AATD) patient is to avoid cigarette smoking.

Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls.

Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).

The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.

References

Template:WikiDoc Sources